新型β-内酰胺酶抑制剂药物研究进展  

Progress on the novelβ-lactamase inhibitors

作　　者：严茹钰 沈瀚 曹小利 Yan Ruyu;Shen Han;Cao Xiaoli(Department of Laboratory Medicine,Nanjing Drum Tower Hospital,Nanjing University of Traditional Chinese Medicine,Nanjing 210008)

机构地区：[1]南京中医药大学鼓楼临床医学院,南京鼓楼医院,检验科,南京210008

出　　处：《中国抗生素杂志》2024年第12期1360-1367,共8页Chinese Journal of Antibiotics

基　　金：国家自然科学基金(No.81902124)。

摘　　要：多重耐药革兰阴性菌的不断出现及流行严重限制了抗感染治疗用抗菌药物的选择,β-内酰胺酶的产生是其耐药的主要机制。因此,针对β-内酰胺酶开发的抑制剂也成为研究热点。近年来,已有多种新型β-内酰胺酶抑制剂药物问世或已投入临床使用。这些抑制剂的研发不仅为治疗多重耐药革兰阴性菌感染提供了新的希望,而且也为抗菌药物的再利用和研发提供了重要思路。本文将对这些抑制剂的化学结构、抗菌机制以及临床应用进行深入探讨,以期为临床用药提供更可靠的依据。The continuous emergence and widespread prevalence of multidrug-resistant Gram-negative bacteria severely limit the selection of antimicrobial agents for anti-infective therapy,with the production ofβ-lactamases being the primary mechanism of resistance.Consequently,the development of inhibitors targetingβ-lactamases has become a research hotspot.In recent years,several novelβ-lactamase inhibitors have emerged or been introduced into clinical practice.The development of these inhibitors not only provides new hope for treating infections caused by multidrug-resistant Gram-negative bacteria but also offers important insights for the reuse and development of antimicrobial agents.This article delved into the chemical structures,antimicrobial mechanisms,and clinical applications of these inhibitors,aiming to provide more reliable guidance for clinical drug use.

关 键 词：Β-内酰胺酶抑制剂 医院获得性感染 革兰阴性菌 多重耐药 

分 类 号：R978.1[医药卫生—药品]